Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZSP1273 + oseltamivir
- Development stage
- Unknown
- Lead developer
- Raynovent Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZSP1273 + oseltamivir is an **oral fixed-dose combination of two antiviral drugs** with distinct mechanisms used for the treatment of influenza A infection, including oseltamivir-resistant strains. ZSP1273 (Onradivir) is a novel, potent inhibitor of the influenza A virus RNA polymerase PB2 subunit, showing efficacy against multidrug-resistant influenza A and B viruses. Oseltamivir is a viral neuraminidase inhibitor widely used to treat and prevent influenza. Preclinical and clinical studies demonstrate that the combination confers strong synergistic antiviral effects, significantly reduces viral titers, mitigates infection severity, and lowers mortality compared to monotherapy. The combination is intended to enhance therapeutic efficacy and reduce resistance development by acting on independent viral targets.
- Brand names
- Onradivir
- Other names
- ZSP1273 + oseltamivir
02
Targets
Neuraminidase
Beyond the preview
Go deeper on ZSP1273 + oseltamivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZSP1273 + oseltamivir.